fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Collision with Deer Results in Fatality on US 79

GUTHRIE, Ky. (5/21/15) — According to a Kentucky State Police report, KSP is investigating a single vehicle, fatality… Read More

Leadership Dynamics Class Raises Funds for MCAS

MARSHALL COUNTY, Ky. (5/21/15) — The Leadership Dynamics Class at Marshall County High School, a continuance of the… Read More
1 DOW 18,232.02
-53.72 (-0.29%)    
2 S&P 2,126.06
-4.76 (-0.22%)    
3 NASDAQ 5,089.36
-1.43 (-0.03%)    

Most Read This Week

May 19, 2015 5457

Owensboro Health Proposes Building $15M Health…

by Doreen Dennis, SurfKY News
May 22, 2015 5293

Madisonville Man Charged with First-Degree Rape

by SurfKY News
May 18, 2015 3886

Madisonville Man Wanted for Attempted Murder in…

by SurfKY News
May 19, 2015 3710

Two Charged with Marijuana Possession after…

by SurfKY News
May 20, 2015 3274

Pennyrile Forest State Resort Park Holding Beach…

by Gil Lawson

Most Read This Month

May 15, 2015 10320

New Madisonville Business In Full Operation Soon

by Tammy Holloway, SurfKY News
May 15, 2015 7310

Investigation of Local Barber Shop Leads to Drug…

by SurfKY News

Stories Trending Now

May 22, 2015 5293

Madisonville Man Charged with First-Degree Rape

by SurfKY News
May 22, 2015 1013

Authorities Searching for Missing 5-Year-Old Boy

by Doreen Dennis, SurfKY News
May 22, 2015 793

Madisonville Police Arrest Reports - May 22, 2015

by SurfKY News
May 22, 2015 643

Hopkins County Sheriff's Reports Released

by SurfKY News
May 22, 2015 617

One Vehicle Collision Sends One to ER

by SurfKY News
May 22, 2015 547

Governor Announces Hopkins County as Kentucky…

by Doreen Dennis, SurfKY News
May 22, 2015 538

Post 2 Telecommunicator among KSP Graduating Class

by Trooper Stu Recke
May 22, 2015 491

MPD Seeks Three in Residential Robbery

by SurfKY News
May 22, 2015 408

Omni Visions Seeks to Recruit Foster Families

by Karen Jones
May 22, 2015 382

Alleged Prescription Drug Fraud Leads to Charges

by SurfKY News